Thrombosis News and Research

Latest Thrombosis News and Research

Exploring biological characteristics of SARS-CoV-2-induced myocardial damage

In a new study, researchers used bioinformatics tools to explore the biological characteristics of SARS-CoV-2-infected myocardium.

19 Jan 2022

Study finds SARS-CoV-2 infection caused significant changes in the levels of stress associated small RNAs

In this study, researchers described the effect of significant changes of small RNAs in the post-transcriptional regulatory network.

13 Jan 2022

Fewer than 1 in 5 U.S. adults with Type 2 diabetes meet targets to reduce heart disease risk

Fewer than 1 in 5 adults with Type 2 diabetes in the U.S. are meeting targets to reduce heart disease risk. Fortunately, available therapies can help when combined with new approaches that address social determinants of health and other barriers to care, according to a new American Heart Association scientific statement published today in the Association's flagship journal Circulation.

10 Jan 2022

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

The LIVE-AIR phase 3 clinical trial is associated with early treatment of hyperinflammatory response with the humanized monoclonal antibody lenzilumab in COVID-19 patients with decreased oxygen saturation. The study results are posted to the medRxiv* preprint server.

6 Jan 2022

Oral bacteria-based SARS-CoV-2 vaccine platform

In a new study, researchers engineered the bacterial strain, Salmonella, to express differently-sized antigens to serve as vaccine platforms.

5 Jan 2022

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

Researcers determine the risk of symptomatic and asymptomatic SARS-CoV-2 infection on post-acute cardiovascular events and all-cause mortality.

4 Jan 2022

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

One dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptomatic COVID-19 and 91.7% effective against severe COVID-19 disease beginning 28 days postvaccination, according to a phase 3 randomized controlled trial published in The Lancet.

23 Dec 2021

Molecular mechanism of SARS-Cov-2-induced thrombosis

Researchers demonstrate that the exposure of platelets to the SARS-CoV-2 spike protein promotes their activation and adhesion.

21 Dec 2021

Insight into COVID-19 brain complications

In this interview, we speak to Professor Scott H. Faro about his latest research that looked into COVID-19 and its complications within the central nervous system.

21 Dec 2021

SARS-CoV-2 infection leads to distinct changes in proteomic and peptidomic profiles and posttranslational modifications

A new study indicates that as a result of SARS-CoV-2 infection comprehensive changes in protein processing and regulation occur.

20 Dec 2021

Study says COVID mRNA-based vaccines best for booster vaccination

A new study looks at the adaptive immune response to COVID-19 vaccines, wherein the authors compare heterologous to homologous immunization.

19 Dec 2021

Treatment for high blood pressure during pregnancy appears safe and reduces maternal risk

Treatment for high blood pressure during pregnancy appears safe for many women and may reduce maternal risk for severe hypertension without increasing fetal and neonatal risks, according to a new American Heart Association scientific statement published today in the Association's journal Hypertension.

16 Dec 2021

Thrombosis may increase mortality risk in hospitalized COVID-19 patients

A team of US-based scientists has recently explored various risk factors associated with the poor prognosis of coronavirus disease 2019 (COVID-19). They have identified thrombosis-related risk factors as a major predictor of in-hospital COVID-19 related mortality. The study is currently available on the medRxiv* preprint server while awaiting peer review.

14 Dec 2021

Study may offer insights into novel therapeutic strategies to treat COVID-19 related blood clots

Blood clots or thromboembolic complications in patients with COVID-19 are associated with increased levels of various proteins that cause blood to clot, compared with people with blood clots unrelated to COVID-19, according to a small study by Yale Cancer Center researchers.

14 Dec 2021

New technology could help determine COVID-19 patients at risk for micro thrombosis-related issues

Physicians treating coronavirus infections have a new diagnostic that could help identify patients at risk of organ failure.

13 Dec 2021

Impact of tumor environments on susceptibility and course of disease in those infected with SARS-CoV-2

A review assessed the impact of "hot" vs. "cold" immune/tumor environments (and associated therapies) on susceptibility and disease course in subjects with these two types of tumors and infected with SARS-CoV-2 to decipher the mechanisms that drive these adverse outcomes in COVID-19 infected cancer patients.

13 Dec 2021

Environmental exposure to low-levels of toxic metals may increase risk of clogged arteries

Environmental exposure to low-levels of the toxic metals arsenic, cadmium and titanium appears to increase the risk of plaque buildup in arteries in the neck, heart and legs, according to new research published today in the American Heart Association's journal Arteriosclerosis, Thrombosis and Vascular Biology (ATVB).

9 Dec 2021

Study reveals how a protein in the blood is attracted to key component of Adenovirus-based vaccines

A collaborative team from the School of Medicine at the University of Cardiff, Wales and a range of US institutions used the UK's national synchrotron, Diamond Light Source, to help reveal the details of how a protein in the blood is attracted to a key component of Adenovirus based vaccines.

8 Dec 2021

Hypercoagulability of the blood responsible for cardiac thrombosis in COVID-19 patients

Researchers examined autopsy tissue samples of hearts from patients who died early in the COVID-19 pandemic.

7 Dec 2021

Octapharma USA announces FDA approval of cutaquig 16.5% for pediatric PI patients

Octapharma USA today announced the U.S. Food & Drug Administration has approved cutaquig [Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution] for the treatment of pediatric patients age 2 and older with primary humoral immunodeficiency (PI). The FDA previously approved cutaquig for adults with PI.

7 Dec 2021

Thrombosis News and Research

Latest Thrombosis News and Research

Exploring biological characteristics of SARS-CoV-2-induced myocardial damage

Study finds SARS-CoV-2 infection caused significant changes in the levels of stress associated small RNAs

Fewer than 1 in 5 U.S. adults with Type 2 diabetes meet targets to reduce heart disease risk

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

Oral bacteria-based SARS-CoV-2 vaccine platform

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

Molecular mechanism of SARS-Cov-2-induced thrombosis

Insight into COVID-19 brain complications

SARS-CoV-2 infection leads to distinct changes in proteomic and peptidomic profiles and posttranslational modifications

Study says COVID mRNA-based vaccines best for booster vaccination

Treatment for high blood pressure during pregnancy appears safe and reduces maternal risk

Thrombosis may increase mortality risk in hospitalized COVID-19 patients

Study may offer insights into novel therapeutic strategies to treat COVID-19 related blood clots

New technology could help determine COVID-19 patients at risk for micro thrombosis-related issues

Impact of tumor environments on susceptibility and course of disease in those infected with SARS-CoV-2

Environmental exposure to low-levels of toxic metals may increase risk of clogged arteries

Study reveals how a protein in the blood is attracted to key component of Adenovirus-based vaccines

Hypercoagulability of the blood responsible for cardiac thrombosis in COVID-19 patients

Octapharma USA announces FDA approval of cutaquig 16.5% for pediatric PI patients

Mastering RNA extraction for plant and fungal research – eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Thrombosis News and Research

Latest Thrombosis News and Research

Mastering RNA extraction for plant and fungal research – eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in